Aurinia Pharmaceuticals (AUPH) Tops Q4 EPS by $1.38, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of $1.53, $1.38 better than the analyst estimate of $0.15. Revenue for the quarter came in at $77.1 million versus the consensus estimate of $74.41 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• JPMorgan Starts BSE Limited (BSE:IN) at Neutral